Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Jade Biosciences announced the first participant has been dosed in JUNIPER, its Phase 2 clinical trial of JADE101 for IgA nephropathy. The open-label trial will evaluate safety, tolerability, and efficacy in approximately 30 participants, with interim data expected in 2027.
Key figures
- Drug Name
- JADE101
- Phase Of Trial
- Phase 2
- Trial name
- JUNIPER
- Serum half life
- 27 days
- Dosing frequency
- every eight weeks
- Participant count
- 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.